Paper of the Day - Migraine drug offers extended benefit
Patients who take the migraine prophylaxis drug topiramate for six months carry on receiving benefit after they stop, suggests new data.
Dutch researchers studied 599 patients who had been successfully treated with the drug for 26 weeks then randomly assigned them to continue with the drug or switch to placebo.
Although the average number of migraine days rose in the placebo group by 1.2 days in four weeks – compared to 0.1 with topiramate – they did not return to pre-treatment levels.
The authors say their data suggests patrients should be treated for six months, with the option to continue to 12 months for those who saw greatest benefit with the drug.
Lancet Neurology published online 6 December